Availability of genome-matched therapy based on clinical practice

Background Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies to improve the current status from a clinical...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2024-07, Vol.29 (7), p.964-971
Main Authors: Hayashi, Naomi, Mori, Seiichi, Ohmoto, Akihiro, Fukada, Ippei, Yamazaki, Masumi, Hosonaga, Mari, Wang, Xiaofei, Ueki, Arisa, Kiyotani, Kazuma, Tonooka, Akiko, Takeuchi, Kengo, Takahashi, Shunji
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cancer Research
Clinical medicine
Female
Genomes
Genomics
Genomics - methods
Head & neck cancer
Humans
Lung cancer
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasms - genetics
Neoplasms - therapy
Oncology
Original
Original Article
Precision Medicine
Sarcoma
Sarcoma - genetics
Sarcoma - therapy
Surgical Oncology
Thyroid cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Comprehensive genomic profiling (CGP) provides new opportunities for patients with advanced cancer to receive genome-matched therapies, but the availability rate of these remains low. We reviewed our CGP cases and suggested possible strategies to improve the current status from a clinical perspective. Methods Druggable genomic alterations and barriers to accessing genome-matched therapies were investigated in 653 patients with 30 various types of cancers who underwent CGP. Results While the availability rate of genome-matched therapies as a whole was 9.5%, CGP was useful in some cancer types. Patients with thyroid cancer and lung cancer harbored druggable genomic alterations at high rates, while sarcoma rarely harbored these alterations (100%, 76%, and 15.2%, respectively). In contrast, the availability rate of genome-matched therapies was highest in patients with sarcoma and head and neck cancer (HNC) (60% and 40%, respectively). One hundred thirteen patients (63.5%) had multiple barriers to accessing genome-matched therapy. Of 178 patients, 21 patients (11.8%) could not be considered for genome-matched therapies solely because of the deterioration of their performance status. Conclusion This study demonstrated the usefulness of CGP for patients with sarcoma and HNC in addition to lung cancer in clinical practice. Performing CGP at the front line has the potential to improve the availability of genome-matched therapy.
ISSN:1341-9625
1437-7772
1437-7772
DOI:10.1007/s10147-024-02533-z